Pharming Group N.V.

NASDAQ:PHAR

Biotechnology

Healthcare
$12.48 +2.19%

+$0.28 today

Market cap
$882.43M
Beta
0.10
P/E (TTM)
77.0
EPS (TTM)
$0.02
52W Low $9.54High $21.34

Volume 0.01M

Average 0.01M

PHAR Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Pharming Group N.V.NASDAQ: PHAR

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares growth accelerates

Q1 FY2026 weighted avg shares of 70.14M shares rose 4.8% year over year, ahead of the -5.0% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 5.8% from the prior quarter. Over 3 fiscal years it compounded at -4.8% a year.

Context

  • Weighted avg shares increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +4.8% holds above the trailing-twelve-month pace of -5.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
70.14M+5.8% QoQ
Last fiscal yearDec 2025
71.32M+3.5% YoY
LTMMar 2026
67.56M-5.0% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+4.8%——
1 year+3.5%——
3-year CAGR-4.8%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
71.32M USD
Year-over-year change
+3.5%
4-year CAGR
-5.0%

Weighted Avg Shares vs competitors

How PHAR compares with its peers on the latest reported figures

  • PHAR's LTM Mar 2026 weighted avg shares of 67.56M shares is the 7th highest of the 10 companies compared; the peer median is 110.2M shares.
  • Its year-over-year change of -5.0% is the lowest of 9, against a peer median of +9.8%.
  • Over three fiscal years its annual growth of -4.8% compares with a peer median of +13.7%.
PHAR Competitors Peer median
Weighted Avg Shares for PHAR and competitors
Company Period LTM YoY 3-year CAGR
BCRXBioCryst Pharmaceuticals, Inc.LTM Jun 2026229.47M +10.2%+4.1%
BMRNBioMarin Pharmaceutical Inc.LTM Sep 2026192.71M +0.7%+1.2%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026164.62M +3.4%+4.1%
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026111.46M +12.7%+17.7%
NTLAIntellia Therapeutics, Inc.LTM Mar 2026110.2M +9.3%+12.1%
PRQRProQR Therapeutics N.V.LTM Mar 2026104.77M +19.6%+13.7%
PHARPharming Group N.V.LTM Mar 202667.56M -5.0%-4.8%
PHVSPharvaris N.V.LTM Sep 202665.72M +16.6%+20.8%
STOKStoke Therapeutics, Inc.LTM Mar 202659.6M +5.0%+15.0%
SLNSilence Therapeutics plcLTM Mar 202631.49M —+63.9%
Peer median (excluding PHAR) 110.2M+9.8%+13.7%

Competitors are the stored peer set for PHAR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue225.46M205.62M245.32M307.75M377.18M
Cost of Revenue23.97M17.56M25.21M36.66M45.63M
Gross Profit201.49M188.06M220.1M271.09M331.56M
Gross Margin89.4%91.5%89.7%88.1%87.9%
Research & Development79.78M52.53M68.91M86.1M98.08M
Selling, General & Admin54.56M68.85M87.5M102.74M117.44M
Operating Expenses186.12M169.83M225.49M280.02M309.75M
Depreciation & Amortization22.23M13.19M15.93M16.64M10.76M
EBITDA55.3M33.53M9.88M16.89M31.7M
EBITDA Margin24.5%16.3%4.0%5.5%8.4%
Operating Income15.37M18.23M(5.39M)(8.93M)20.88M
Operating Margin6.8%8.9%-2.2%-2.9%5.5%
Interest Income59.99K85K3.53M5.92M2.56M
Interest Expense7M5.36M5.96M9.05M21.31M
Other Income / Expenses10.79M(3.25M)(6.63M)133.58K(8.03M)
Income Before Tax26.16M14.99M(12.01M)(8.79M)12.88M
Pre-Tax Margin11.6%7.3%-4.9%-2.9%3.4%
Income Tax Expense8.03M1.31M(1.46M)3.47M10.34M
Net Income18.13M13.67M(10.55M)(12.26M)2.86M
Net Margin8.0%6.7%-4.3%-4.0%0.8%
EPS (Basic)0.230.17(0.14)(0.18)0.04
EPS (Diluted)0.210.16(0.14)(0.18)0.04
Weighted Avg Shares87.64M82.54M65.7M68.92M71.32M
Weighted Avg Shares (Diluted)87.64M84.28M65.7M68.92M71.32M

Pharming Group N.V.

NASDAQ:PHAR

Intrinsic Alpha fair value

Locked

Current Price

$12.48

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.